665 related articles for article (PubMed ID: 25953744)
1. Hypertrophic Cardiomyopathy in Adulthood Associated With Low Cardiovascular Mortality With Contemporary Management Strategies.
Maron BJ; Rowin EJ; Casey SA; Link MS; Lesser JR; Chan RH; Garberich RF; Udelson JE; Maron MS
J Am Coll Cardiol; 2015 May; 65(18):1915-28. PubMed ID: 25953744
[TBL] [Abstract][Full Text] [Related]
2. Hypertrophic Cardiomyopathy in Children, Adolescents, and Young Adults Associated With Low Cardiovascular Mortality With Contemporary Management Strategies.
Maron BJ; Rowin EJ; Casey SA; Lesser JR; Garberich RF; McGriff DM; Maron MS
Circulation; 2016 Jan; 133(1):62-73. PubMed ID: 26518766
[TBL] [Abstract][Full Text] [Related]
3. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy.
Maron BJ; Spirito P; Ackerman MJ; Casey SA; Semsarian C; Estes NA; Shannon KM; Ashley EA; Day SM; Pacileo G; Formisano F; Devoto E; Anastasakis A; Bos JM; Woo A; Autore C; Pass RH; Boriani G; Garberich RF; Almquist AK; Russell MW; Boni L; Berger S; Maron MS; Link MS
J Am Coll Cardiol; 2013 Apr; 61(14):1527-35. PubMed ID: 23500286
[TBL] [Abstract][Full Text] [Related]
4. Risk stratification and outcome of patients with hypertrophic cardiomyopathy >=60 years of age.
Maron BJ; Rowin EJ; Casey SA; Haas TS; Chan RH; Udelson JE; Garberich RF; Lesser JR; Appelbaum E; Manning WJ; Maron MS
Circulation; 2013 Feb; 127(5):585-93. PubMed ID: 23275385
[TBL] [Abstract][Full Text] [Related]
5. Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators.
Maron BJ; Casey SA; Olivotto I; Sherrid MV; Semsarian C; Autore C; Ahmed A; Boriani G; Francia P; Winters SL; Giudici M; Koulova A; Garberich R; Rowin EJ; Sears SF; Maron MS; Spirito P
Circ Arrhythm Electrophysiol; 2018 Apr; 11(4):e005820. PubMed ID: 29625970
[TBL] [Abstract][Full Text] [Related]
6. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P
JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294
[TBL] [Abstract][Full Text] [Related]
7. Modes of death and clinical outcomes in adult patients with hypertrophic cardiomyopathy in Thailand.
Songsirisuk N; Kittipibul V; Methachittiphan N; Charoenattasil V; Zungsontiporn N; Spanuchart I; Buppajarntham S; Mankongpaisarnrung C; Satitthummanid S; Srimahachota S; Chattranukulchai P; Boonyaratavej Songmuang S; Puwanant S
BMC Cardiovasc Disord; 2019 Jan; 19(1):1. PubMed ID: 30606129
[TBL] [Abstract][Full Text] [Related]
8. Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy: patient outcomes, rate of appropriate and inappropriate interventions, and complications.
Vriesendorp PA; Schinkel AF; Van Cleemput J; Willems R; Jordaens LJ; Theuns DA; van Slegtenhorst MA; de Ravel TJ; ten Cate FJ; Michels M
Am Heart J; 2013 Sep; 166(3):496-502. PubMed ID: 24016499
[TBL] [Abstract][Full Text] [Related]
9. The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy.
O'Mahony C; Lambiase PD; Quarta G; Cardona M; Calcagnino M; Tsovolas K; Al-Shaikh S; Rahman SM; Arnous S; Jones S; McKenna W; Elliott P
Heart; 2012 Jan; 98(2):116-25. PubMed ID: 21757459
[TBL] [Abstract][Full Text] [Related]
10. Contemporary strategies for risk stratification and prevention of sudden death with the implantable defibrillator in hypertrophic cardiomyopathy.
Maron BJ; Maron MS
Heart Rhythm; 2016 May; 13(5):1155-1165. PubMed ID: 26749314
[TBL] [Abstract][Full Text] [Related]
11. Causes of death and mortality in hypertrophic cardiomyopathy patients with implantable defibrillators in Sweden.
Magnusson P; Gadler F; Liv P; Mörner S
J Cardiovasc Med (Hagerstown); 2016 Jul; 17(7):478-84. PubMed ID: 26808417
[TBL] [Abstract][Full Text] [Related]
12. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up.
Syska P; Przybylski A; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Gepner K; Pytkowski M; Kowalik I; Maczyńska-Mazuruk R; Ruzyłło W; Szwed H
J Cardiovasc Electrophysiol; 2010 Aug; 21(8):883-9. PubMed ID: 20132378
[TBL] [Abstract][Full Text] [Related]
13. Hypertrophic Cardiomyopathy and Implantable Defibrillators in Sweden: Inappropriate Shocks and Complications Requiring Surgery.
Magnusson P; Gadler F; Liv P; Mörner S
J Cardiovasc Electrophysiol; 2015 Oct; 26(10):1088-94. PubMed ID: 26178879
[TBL] [Abstract][Full Text] [Related]
14. Determinants of patient survival rate after implantation of a cardioverter-defibrillator without resynchronisation capability.
Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
Kardiol Pol; 2012; 70(11):1099-110. PubMed ID: 23180517
[TBL] [Abstract][Full Text] [Related]
15. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy.
Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245
[TBL] [Abstract][Full Text] [Related]
16. Risk factors and mode of death in isolated hypertrophic cardiomyopathy in children.
Decker JA; Rossano JW; Smith EO; Cannon B; Clunie SK; Gates C; Jefferies JL; Kim JJ; Price JF; Dreyer WJ; Towbin JA; Denfield SW
J Am Coll Cardiol; 2009 Jul; 54(3):250-4. PubMed ID: 19589438
[TBL] [Abstract][Full Text] [Related]
17. Hypertrophic cardiomyopathy: risk factors for life and living benefits insurance.
Pokorski RJ
J Insur Med; 2002; 34(1):43-60. PubMed ID: 15303593
[TBL] [Abstract][Full Text] [Related]
18. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine.
Maron BJ; Ommen SR; Semsarian C; Spirito P; Olivotto I; Maron MS
J Am Coll Cardiol; 2014 Jul; 64(1):83-99. PubMed ID: 24998133
[TBL] [Abstract][Full Text] [Related]
19. Hypertrophic Cardiomyopathy With Left Ventricular Apical Aneurysm: Implications for Risk Stratification and Management.
Rowin EJ; Maron BJ; Haas TS; Garberich RF; Wang W; Link MS; Maron MS
J Am Coll Cardiol; 2017 Feb; 69(7):761-773. PubMed ID: 28209216
[TBL] [Abstract][Full Text] [Related]
20. Low Risk of Hypertrophic Cardiomyopathy With Contemporary Management Strategies Implemented in Non-Referral Regional Community-Based Practices.
Shirani J; Aurshiya R; Elshaikh A; Olenchock SA; Rowin EJ; Maron MS; Maron BJ
Am J Cardiol; 2021 Mar; 142():130-135. PubMed ID: 33279482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
